Vivos surges on FDA nod for pediatric sleep apnea device

seekingalpha09-19

Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468553156?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg","is_english":true,"pubTime":"2024-09-19 01:25","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2468553156","market":"sh","top_or_hot":-1,"title":"Vivos surges on FDA nod for pediatric sleep apnea device","media":"seekingalpha","content":"<div>\n<p>Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) ...</p>\n\n<a href=\"https://seekingalpha.com/news/4150816-vivos-stock-surges-fda-nod-osa-device\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos surges on FDA nod for pediatric sleep apnea device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos surges on FDA nod for pediatric sleep apnea device\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 01:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4150816-vivos-stock-surges-fda-nod-osa-device><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) ...</p>\n\n<a href=\"https://seekingalpha.com/news/4150816-vivos-stock-surges-fda-nod-osa-device\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHG","symbol_name":"飞利浦","start_time":0,"source_url":"https://seekingalpha.com/news/4150816-vivos-stock-surges-fda-nod-osa-device","article_id":"2468553156","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468553156","pubTimestamp":1726680342,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Vivos Therapeutics  climbed on Wednesday after MedTech announced the FDA's 510 clearance for its DNA appliance as a treatment for children with obstructive sleep apnea  and snoring. Accordingly, DNA, Vivos'  flagship oral medical device, will be available in the U.S. to reduce snoring and treat moderate to severe OSA in children aged 6 to 17. The company called the device a medical breakthrough, noting that surgical interventions tend to fail in children with OSA. Meanwhile, given their impact on growth, CPAP devices such as those manufactured by ResMed  and Philips  are not widely prescribed for the age group.  \"The FDA 510 clearance announced today is, to our knowledge, the first time any oral medical device has ever been approved to treat moderate to severe OSA in children,\" CEO Kirk Huntsman added.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHG":"飞利浦","BK4196":"保健护理服务","RMD":"瑞思迈","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","VVOS":"Vivos Therapeutics","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK4504":"桥水持仓","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC"},"translate_title":"Vivos因FDA批准儿科睡眠呼吸暂停设备而股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHG":1,"RMD":1,"VVOS":1},"content_text":"Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its DNA appliance as a treatment for children with obstructive sleep apnea (OSA) and snoring. Accordingly, DNA, Vivos' (VVOS) flagship oral medical device, will be available in the U.S. to reduce snoring and treat moderate to severe OSA in children aged 6 to 17. The company called the device a medical breakthrough, noting that surgical interventions tend to fail in children with OSA. Meanwhile, given their impact on growth, CPAP devices such as those manufactured by ResMed (RMD) and Philips (PHG) are not widely prescribed for the age group.  \"The FDA 510(k) clearance announced today is, to our knowledge, the first time any oral medical device has ever been approved to treat moderate to severe OSA in children,\" CEO Kirk Huntsman added.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468553156"}